Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

ESMO Open

article

V. Di Lauro¹  G. Barchiesi²  F. Martorana³  G. Zucchini⁴  M. Muratore⁵  C. Fontanella⁶  G. Arpino⁷  L. Del Mastro⁸  M. Giuliano⁷  F. Puglisi^1,10  M. De Laurentiis¹ 

[1] Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale;Department of Radiology, Oncology and Pathology Science, University of Rome La Sapienza;Department of Clinical and Experimental Medicine, University of Catania;Oncology Department, Michele e Pietro Ferrero Hospital;Department of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS;Oncology Unit;Department of Clinical Medicine and Surgery, University of Naples Federico II;Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino;Department of Internal Medicine and Medical Specialties ,(DIMI), School of Medicine, University of Genoa;Department of Medical Oncology;Department of Medicine ,(DAME), University of Udine

关键词: health-related quality of life;    cyclin-dependent 4/6 inhibitors;    abemaciclib;    palbociclib;    ribociclib;   

DOI  :  10.1016/j.esmoop.2022.100629

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background Evaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance and is now a key determinant of anticancer treatments' value. HR-QoL has been assessed in trials testing cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in breast cancer (BC), using various questionnaires at different timepoints. HR-QoL reports from BC patients treated with CDK4/6i in the real-world setting are also available.Methods We systematically reviewed the literature, searching for full-length articles, and selected conference abstracts reporting data on HR-QoL in BC patients at any stage and of any molecular subtype treated with abemaciclib, palbociclib or ribociclib.Results A total of 533 full-length articles and 143 abstracts were retrieved. After screening for eligibility, 38 records were included (31 clinical trials; 7 real-world reports). Assessment methods were heterogeneous across studies in terms of questionnaires, evaluation timepoints and endpoints.Overall, adding CDK4/6i to endocrine therapy did not worsen patients' HR-QoL, with a positive trend towards pain improvement. Gastrointestinal scores (diarrhea, nausea and appetite loss) statistically favored the control arm among metastatic BC patients receiving abemaciclib, whereas they were superimposable in the early setting. The combination of palbociclib and endocrine therapy showed similar HR-QoL outcomes compared with endocrine therapy alone, but determined better scores compared with chemotherapy. HR-QoL was specifically assessed in premenopausal patients treated with ribociclib, showing similar scores compared with postmenopausal patients.Conclusions Despite methodological heterogeneity does not allow a proper comparison, HR-QoL was generally maintained with CDK4/6i. However, differences between abemaciclib, palbociclib and ribociclib exist and mainly rely on the distinct safety profiles of the compounds. These differences should be acknowledged and taken into account in the clinical practice.

【 授权许可】

CC BY|CC BY-NC-ND